In vivo antitumor effect of an intracellular single-chain antibody fragment against the E7 oncoprotein of human papillomavirus 16

International Journal of Cancer

Volumn 134, Issue 11, 2014, Pages 2742-2747

  Accardi, Luisa ^a   Paolini, Francesca ^b   Mandarino, Angela ^a   Percario, Zulema ^c   Di Bonito, Paola ^a   Di Carlo, Valentina ^a   Affabris, Elisabetta ^c   Giorgi, Colomba ^a   Amici, Carla ^d   Venuti, Aldo ^b  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^b REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^c ROMA TRE UNIVERSITY   (Italy)

^d UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

cancer therapy; E7 oncoprotein; human papillomaviruses; intrabodies; scFv

Indexed keywords

PROTEIN E7; RETROVIRUS VECTOR; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CELL PROLIFERATION; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DRUG MECHANISM; EMBRYO; ENDOPLASMIC RETICULUM; FEMALE; HUMAN PAPILLOMAVIRUS TYPE 16; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN LOCALIZATION; TUMOR CELL;

CANCER THERAPY; E7 ONCOPROTEIN; HUMAN PAPILLOMAVIRUSES; INTRABODIES; SCFV;

ANIMALS; ANTIBODIES, VIRAL; CELL PROLIFERATION; FEMALE; GENETIC THERAPY; HUMAN PAPILLOMAVIRUS 16; HUMANS; MICE; MICE, INBRED C57BL; PAPILLOMAVIRUS E7 PROTEINS; PAPILLOMAVIRUS INFECTIONS; SINGLE-CHAIN ANTIBODIES; SURVIVAL RATE; TUMOR CELLS, CULTURED; UTERINE CERVICAL NEOPLASMS;

EID: 84896396415     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28604     Document Type: Article

References (31)

1. Zur Hausen H,. Papillomavirus infections: a major cause of human cancer. In:, zur Hausen, H, ed. Infections causing human cancer. Weinheim: WILEY-VCH Verlag GmbH & Co. KGaA, 2006. 145-243.
2. Forman D, de Martel C, Lacey CJ, et al. Global burden of human papillomavirus and related diseases. Vaccine 2012; 30: F12-23.
3. Stanley MA,. Genital human papillomavirus infections: current and prospective therapies. J Gen Virol 2012; 93: 681-91.
4. Moody CA, Laimins A,. Human papillomavirus oncoproteins: pathways to transformation. Nature 2010; 10: 550-60.
5. Ghittoni R, Accardi R, Hasan U, et al. The biological properties of E6 and E7 oncoproteins from human papillomaviruses. Virus Genes 2010; 40: 1-13.
6. Tan S, de Vries EG, van der Zee AG, et al. Anticancer drugs aimed at E6 and E7 activity in HPV-positive cervical cancer. Curr Cancer Drug Targets 2012; 12: 170-84.
7. Holliger P, Hudson PJ,. Engineered antibody fragments and the rise of single domains. Nat Biotechnol 2005; 23: 1126-36.
8. Accardi L, Di Bonito P,. Antibodies in single-chain format against tumour-associated antigens: present and future applications. Curr Med Chem 2010; 17: 1730-55.
9. Lener M, Horn IR, Cardinale A, et al. Diverting a protein from its cellular location by intracellular antibodies. The case of p21Ras. Eur J Biochem 2000; 267: 1196-205.
10. Perez-Martinez D, Tanaka T, Rabbitts TH,. Intracellular antibodies and cancer: new technologies offer therapeutic opportunities. Bioessays 2010; 32: 589-98.
11. Hong CW, Zeng Q,. Awaiting a new era of cancer immunotherapy. Cancer Res 2012; 2: 3715-29.
12. Accardi L, Donà MG, Di Bonito P, et al. Intracellular anti-E7 human antibodies in single-chain format inhibit proliferation of HPV16-positive cervical carcinoma cells. Int J Cancer 2005; 116: 564-70.
13. Donà MG, Giorgi C, Accardi L,. Characterization of antibodies in single-chain format against the E7 oncoprotein of the human papillomavirus type 16 and their improvement by mutagenesis. BMC Cancer 2007; 7: 25.
14. Accardi L, Donà MG, Mileo AM, et al. Retinoblastoma-independent antiproliferative activity of novel intracellular antibodies against the E7 oncoprotein in HPV16-positive cells. BMC Cancer 2011; 11: 17.
15. Lin KY, Guarnieri FG, Staveley-O'Carroll KF, et al. Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res 1996; 56: 21-6.
16. Feltkamp MC, Smits HL, Vierboom MP, et al. Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells. Eur J Immunol 1993; 23: 2242-9.
17. Knapp AA, Mc Manus PM, Bockstall K, et al. Identification of the nuclear localization and export signals of high risk HPV16 E7 oncoprotein. Virology 2009; 383: 60-8.
18. Dreier K, Scheiden R, Lener B, et al. Subcellular localization of the human papillomavirus 16 E7 oncoprotein in CaSki cells and its detection in cervical adenocarcinoma and adenocarcinoma in situ. Virology 2011; 409: 54-8.
19. Laurson J, Raj K,. Localisation of human papillomavirus 16 E7 oncoprotein changes with cell confluence. PLoS One 2011; 6: e21501.
20. Walter P, Ron D,. The unfolded protein response: from stress pathway to homeostatic regulation. Science 2011; 334: 1081-6.
21. Crook T, Morgenstern JP, Crawford L, et al. Continued expression of HPV-l6 E7protein is required for maintenance of the transformed phenotype of cells co-transformed by HPV-l6 plus EJ-ras. EMBO J 1989; 8: 513-19.
22. Kanodia S, Da Silva DM, Kast WM,. Recent advances in strategies for immunotherapy of human papillomavirus-induced lesions. Int J Cancer 2008; 122: 247-59.
23. Paolini F, Massa S, Manni I, et al. Immunotherapy in new pre-clinical models of HPV-associated oral cancers. Hum Vaccin Immunother 2013; 9.
24. Gu W, Yeo E, McMillan N, et al. Silencing oncogene expression in cervical cancer stem-like cells inhibits their cell growth and self-renewal ability. Cancer Gene Ther 2011; 18: 897-905.
25. Böldicke T,. Blocking translocation of cell surface molecules from the ER to the cell surface by intracellular antibodies targeted to the ER. J Cell Mol Med 2007; 11: 54-70.
26. Zwerschke W, Mannhardt B, Massimi P, et al. Allosteric activation of acid alpha-glucosidase by the human papillomavirus E7 protein. J Biol Chem 2000; 275: 9534-41.
27. Valdovinos-Torres H, Orozco-Morales M, Pedroza-Saavedra A, et al. Different isoforms of HPV-16 E7 protein are present in cytoplasm and nucleus. Open Virol J 2008; 2: 15-23.
28. Lobato MN, Rabbitts TH,. Intracellular antibodies and challenges facing their use as therapeutic agents. Trends Mol Med 2003; 9: 390-6.
29. Giacca M, Zacchigna S,. Virus-mediated gene delivery for human gene therapy. J Control Release 2012; 161: 377-88.
30. Collet G, Grillon C, Nadim M, et al. Trojan horse at cellular level for tumor gene therapies. Gene 2013; 525: 208-16.
31. del Campo JM, Prat A, Gil-Moreno A, et al. Update on novel therapeutic agents for cervical cancer. Gynecol Oncol 2008; 110: S72-6.